BioLife Solutions Inc., a prominent developer and supplier of cell processing tools and services for the cell and gene therapy market, has announced its financial results for the first quarter of 2025. The company reported cell processing revenue of $21.6 million, reflecting a 33% increase compared to the first quarter of 2024. The GAAP gross margin stood at 63%, while the non-GAAP adjusted gross margin was 66%. The company recorded a GAAP net loss of $0.4 million and a non-GAAP adjusted EBITDA of $5.7 million, which accounts for 24% of revenue. In terms of financial guidance for 2025, BioLife Solutions is affirming its revenue outlook, projecting between $95.5 million and $99.0 million, which would represent growth of 16% to 20% compared to 2024. The company expects cell processing platform revenue to range from $86.5 million to $89.0 million, indicating a year-over-year growth of 18% to 21%. Additionally, the evo and Thaw platform revenue is expected to be between $9.0 million and $10.0 million, suggesting a growth of 3% to 15% compared to the previous year. BioLife Solutions also highlighted a significant operational update, having completed the acquisition of PanTHERA CryoSolutions on April 4, 2025. This acquisition enhances the company's position as a leader in the biopreservation market, introducing novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor technology, and bolstering the scientific capabilities of its management team.